| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1220 | 2018 |
| The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ... Cancer discovery 9 (7), 910-925, 2019 | 305 | 2019 |
| Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies JJ Shatzel, SR Olson, DL Tao, OJT McCarty, AV Danilov, TG DeLoughery Journal of thrombosis and haemostasis 15 (5), 835-847, 2017 | 289 | 2017 |
| Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data D Sun, X Guan, AE Moran, LY Wu, DZ Qian, P Schedin, MS Dai, ... Nature biotechnology 40 (4), 527-538, 2022 | 248 | 2022 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer cell 40 (8), 850-864. e9, 2022 | 211 | 2022 |
| The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells JC Godbersen, LA Humphries, OV Danilova, PE Kebbekus, JR Brown, ... Clinical cancer research 20 (6), 1576-1589, 2014 | 131 | 2014 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 114 | 2021 |
| Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma SK Agarwal, AH Salem, AV Danilov, B Hu, S Puvvada, M Gutierrez, ... British journal of clinical pharmacology 83 (4), 846-854, 2017 | 99 | 2017 |
| DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance AV Danilov, D Neupane, AS Nagaraja, EV Feofanova, LA Humphries, ... PloS one 6 (10), e26815, 2011 | 90 | 2011 |
| Cardiac non‐Hodgkin's lymphoma: clinical characteristics and trends in survival MJ Gordon, O Danilova, S Spurgeon, AV Danilov European journal of haematology 97 (5), 445-452, 2016 | 89 | 2016 |
| Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib MJ Gordon, M Churnetski, H Alqahtani, X Rivera, A Kittai, SM Amrock, ... Cancer 124 (15), 3192-3200, 2018 | 84 | 2018 |
| Burkitt lymphoma international prognostic index AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ... Journal of clinical oncology 39 (10), 1129-1138, 2021 | 79 | 2021 |
| Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma S Yi, Y Yan, M Jin, S Bhattacharya, Y Wang, Y Wu, L Yang, E Gine, G Clot, ... The Journal of clinical investigation 132 (3), 2022 | 72 | 2022 |
| Targeted therapy in chronic lymphocytic leukemia: past, present, and future AV Danilov Clinical therapeutics 35 (9), 1258-1270, 2013 | 69 | 2013 |
| Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+ Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic … JG Gribben, W Jurczak, RW Jacobs, S Grosicki, K Giannopoulos, ... Blood 136, 37-39, 2020 | 68 | 2020 |
| Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs MJ Matasar, S Luminari, PM Barr, SK Barta, AV Danilov, BT Hill, ... The oncologist 24 (11), e1236-e1250, 2019 | 62 | 2019 |
| Molecular pathogenesis of chronic lymphocytic leukemia AV Danilov, OV Danilova, AK Klein, BT Huber Current molecular medicine 6 (6), 665-675, 2006 | 62 | 2006 |
| NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B … AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ... Blood 140 (Supplement 1), 2329-2332, 2022 | 61 | 2022 |
| Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule, EA Kio, L Karlin, ... Clinical Cancer Research 26 (12), 2810-2818, 2020 | 61 | 2020 |
| Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia BM Holderness, S Malhotra, NB Levy, AV Danilov Journal of Clinical Oncology 31 (12), e197-e199, 2013 | 59 | 2013 |
Tingting LiuUniversity of California, DavisVerified email at ucdavis.edu